Clinical Research Program

摘要：临床和转译研究计划 认识到北卡罗来纳大学临床研究的基本性质，以及常见的弱点可能是 在许多癌症中被发现，CR进一步投资于从板凳到床边的连续体。我们已经成为 更多地围绕基于组织的研究、新的疗法和技术的主题进行整合 将重点转向研究人员发起的试验(IITs)。在上一次竞争续签中被评为“杰出”的CR 所有癌症类型的广泛临床和研究专业知识以及成像方面的关键相关优势， 统计设计、生物标记物开发、免疫肿瘤学和组织研究。CR主题包括： 1)通过早期阶段和研究人员发起的临床试验开发和评估新疗法；2) 进行以组织为基础的最先进的组学研究，以改进癌症治疗；3)开发新的 癌症的诊断和治疗技术。CR工作的要点和未来计划包括 创新的IITs利用北卡罗来纳大学的研究，在细胞免疫治疗方面的投资和成功记录 试验，将基因组学努力转化为治疗性临床试验，并纳入生物标记物开发， 新的成像和技术进入我们的试验。它由三位充满活力的试验者和内科科学家领导。 迪斯，米洛夫斯基，还有耶。每一项都为项目带来了一套互补的技能：早期阶段试验(DEE)， 基因组学和新药试验(Milowsky)，以及翻译合作研究(YEH)。CR将重点放在 关于集水区疾病和培训下一代临床科学家。CR成员参与了 针对与北卡罗来纳州集水区特别相关的癌症的多项试验。这个 CR计划由60名成员组成，分别与7个基础科学和10个临床科室有关 北卡罗来纳大学-教堂山及其附属机构。在上一个资助期内，会员发表了1,260项癌症- 在相关文章中，34%是方案间的，18%是方案内的(45%是协作的)。2019年， 计划成员持有总额为1870万美元(直接费用)的癌症相关外部资金，包括 来自NCI的520万美元(直接成本)和490万美元的其他同行审查资金。

ABSTRACT: CLINICAL AND TRANSLATIONAL RESEARCH PROGRAM Recognizing the fundamental nature of clinical research at UNC, and that common vulnerabilities may be found across many cancers, CR has further invested in the bench-to-bedside continuum. We have become even more integrated around the themes of tissue-based research, novel therapeutics and technologies with a pivot towards investigator intiated trials (IITs). CR, rated “Outstanding” at the last competitive renewal, has broad clinical and research expertise across all cancer types and key correlative strengths in imaging, statistical design, biomarker development, immuno-oncology, and tissue-based research. CR themes include: 1) Develop and evaluate novel therapies through early phase and investigator-initiated clinical trials; 2) Conduct tissue-based state-of-the-art ‘omics research to improve cancer treatments; 3) Develop new technologies for the diagnosis and treatment of cancer. Highlights of CR work and future plans include innovative IITs leveraging UNC research, an investment and track record of success in cellular immunotherapy trials, translating genomics efforts into therapeutic clinical trials, and incorporating biomarker development, novel imaging, and technologies into our trials. It is led by three dynamic trialists and physician-scientists, Drs. Dees, Milowsky, and Yeh. Each bring a complementary skill set to the program: Early Phase trials (Dees), genomics and novel drug trials (Milowsky), and translational collaborative research (Yeh). CR focuses on catchment area diseases and on training the next generation of clinical scientists. CR members are involved in multiple trials targeting cancers of particular relevance to the catchment area, the state of North Carolina. The CR Program consists of 60 members who are associated with 7 basic science and 10 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, members published 1260 cancer- related articles, 34% were inter-programmatic and 18% were intra-programmatic (45% collaborative). In 2019, program members held grants totaling $18.7M (direct cost) in cancer-relevant extramural funding, including $5.2M (direct costs) from the NCI and $4.9M other peer-reviewed funding.